Biocon Ltd
BIOCON (NSE)

364.40

43,749.86
Proj. ROE (%)
9.80
Proj. P/E (x)
53.71
Proj EV / EBITDA (x)
23.49
Proj. P/BV (x)
5.30
Proj. Revenue ( Cr.)
8,082.56

Stock View

HOLD
Share on
The average score for Biocon Ltd stands at 5 against 3, three months back.

Biocon Limited is a biopharmaceutical company. The Company focuses to reduce therapy costs of chronic diseases like autoimmune, diabetes, and cancer. Through its products and research services it is enabling access to affordable healthcare for patients, partners and healthcare systems across the globe. The Company has developed and taken a range of Novel Biologics, Biosimilars, differentiated Small Molecules and affordable Recombinant Human Insulin and Analogs from Lab to Market. The Company’s brands include INSUGEN (rh-insulin), BASALOG (Glargine), CANMAb (Trastuzumab), BIOMAb-EGFR (Nimotuzumab) and ALZUMAb (Itolizumab), an anti-CD6 monoclonal antibody. It has a pipeline of Biosimilars and Novel Biologics at various stages of development, including Insulin Tregopil, an oral insulin analog.

Disclaimer : All estimates (1 year forward) are based on Consensus View provided by Refinitiv.

Technical Data
50 DMA()
355.25
100 DMA ()
365.25
200 DMA ()
381.52
52 Weeks Range
314.80
487.75
Street View :-
Bearish
Open ZERO Brokerage Demat Account
Open ZERO Brokerage Demat Account

  • 0

    Delivery Brokerage for Lifetime

  • 20

    Per order for Intraday, F&O, Currency & Commodity